Antibody Drug Conjugates (ADCs) Market, Global Outlook and Forecast 2022-2028

April 2022 | 60 pages | ID: AD6CFF2ADC27EN
Market Monitor Global

Abstracts

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.

This report contains market size and forecasts of Antibody Drug Conjugates (ADCs) in Global, including the following market information:

Global Antibody Drug Conjugates (ADCs) Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Antibody Drug Conjugates (ADCs) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Seattle Genetics Technology Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antibody Drug Conjugates (ADCs) include Roche, Pfizer, Novartis, Genmab, Bayer, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and AbGenomics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antibody Drug Conjugates (ADCs) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antibody Drug Conjugates (ADCs) Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Antibody Drug Conjugates (ADCs) Market Segment Percentages, by Type, 2021 (%)

• Seattle Genetics Technology
• ImmunoGen Technology
• Immunomedics Technology

Global Antibody Drug Conjugates (ADCs) Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Antibody Drug Conjugates (ADCs) Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinics
• Others

Global Antibody Drug Conjugates (ADCs) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Antibody Drug Conjugates (ADCs) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antibody Drug Conjugates (ADCs) revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Antibody Drug Conjugates (ADCs) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Pfizer
• Novartis
• Genmab
• Bayer
• Seattle Genetics
• Takeda Pharmaceuticals
• AbbVie
• AbGenomics
• ADC Therapeutics
• Astellas Pharma
• Kairos Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Antibody Drug Conjugates (ADCs) Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Antibody Drug Conjugates (ADCs) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTIBODY DRUG CONJUGATES (ADCS) OVERALL MARKET SIZE

2.1 Global Antibody Drug Conjugates (ADCs) Market Size: 2021 VS 2028
2.2 Global Antibody Drug Conjugates (ADCs) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Antibody Drug Conjugates (ADCs) Players in Global Market
3.2 Top Global Antibody Drug Conjugates (ADCs) Companies Ranked by Revenue
3.3 Global Antibody Drug Conjugates (ADCs) Revenue by Companies
3.4 Top 3 and Top 5 Antibody Drug Conjugates (ADCs) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antibody Drug Conjugates (ADCs) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antibody Drug Conjugates (ADCs) Players in Global Market
  3.6.1 List of Global Tier 1 Antibody Drug Conjugates (ADCs) Companies
  3.6.2 List of Global Tier 2 and Tier 3 Antibody Drug Conjugates (ADCs) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Antibody Drug Conjugates (ADCs) Market Size Markets, 2021 & 2028
  4.1.2 Seattle Genetics Technology
  4.1.3 ImmunoGen Technology
  4.1.4 Immunomedics Technology
4.2 By Type - Global Antibody Drug Conjugates (ADCs) Revenue & Forecasts
  4.2.1 By Type - Global Antibody Drug Conjugates (ADCs) Revenue, 2017-2022
  4.2.2 By Type - Global Antibody Drug Conjugates (ADCs) Revenue, 2023-2028
  4.2.3 By Type - Global Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Antibody Drug Conjugates (ADCs) Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinics
  5.1.4 Others
5.2 By Application - Global Antibody Drug Conjugates (ADCs) Revenue & Forecasts
  5.2.1 By Application - Global Antibody Drug Conjugates (ADCs) Revenue, 2017-2022
  5.2.2 By Application - Global Antibody Drug Conjugates (ADCs) Revenue, 2023-2028
  5.2.3 By Application - Global Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Antibody Drug Conjugates (ADCs) Market Size, 2021 & 2028
6.2 By Region - Global Antibody Drug Conjugates (ADCs) Revenue & Forecasts
  6.2.1 By Region - Global Antibody Drug Conjugates (ADCs) Revenue, 2017-2022
  6.2.2 By Region - Global Antibody Drug Conjugates (ADCs) Revenue, 2023-2028
  6.2.3 By Region - Global Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Antibody Drug Conjugates (ADCs) Revenue, 2017-2028
  6.3.2 US Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.3.3 Canada Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.3.4 Mexico Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Antibody Drug Conjugates (ADCs) Revenue, 2017-2028
  6.4.2 Germany Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.4.3 France Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.4.4 U.K. Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.4.5 Italy Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.4.6 Russia Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.4.7 Nordic Countries Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.4.8 Benelux Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Antibody Drug Conjugates (ADCs) Revenue, 2017-2028
  6.5.2 China Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.5.3 Japan Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.5.4 South Korea Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.5.5 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.5.6 India Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Antibody Drug Conjugates (ADCs) Revenue, 2017-2028
  6.6.2 Brazil Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.6.3 Argentina Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue, 2017-2028
  6.7.2 Turkey Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.7.3 Israel Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.7.4 Saudi Arabia Antibody Drug Conjugates (ADCs) Market Size, 2017-2028
  6.7.5 UAE Antibody Drug Conjugates (ADCs) Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche
  7.1.1 Roche Corporate Summary
  7.1.2 Roche Business Overview
  7.1.3 Roche Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.1.4 Roche Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.1.5 Roche Key News
7.2 Pfizer
  7.2.1 Pfizer Corporate Summary
  7.2.2 Pfizer Business Overview
  7.2.3 Pfizer Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.2.4 Pfizer Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.2.5 Pfizer Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.3.4 Novartis Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Genmab
  7.4.1 Genmab Corporate Summary
  7.4.2 Genmab Business Overview
  7.4.3 Genmab Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.4.4 Genmab Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.4.5 Genmab Key News
7.5 Bayer
  7.5.1 Bayer Corporate Summary
  7.5.2 Bayer Business Overview
  7.5.3 Bayer Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.5.4 Bayer Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.5.5 Bayer Key News
7.6 Seattle Genetics
  7.6.1 Seattle Genetics Corporate Summary
  7.6.2 Seattle Genetics Business Overview
  7.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.6.5 Seattle Genetics Key News
7.7 Takeda Pharmaceuticals
  7.7.1 Takeda Pharmaceuticals Corporate Summary
  7.7.2 Takeda Pharmaceuticals Business Overview
  7.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.7.5 Takeda Pharmaceuticals Key News
7.8 AbbVie
  7.8.1 AbbVie Corporate Summary
  7.8.2 AbbVie Business Overview
  7.8.3 AbbVie Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.8.4 AbbVie Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.8.5 AbbVie Key News
7.9 AbGenomics
  7.9.1 AbGenomics Corporate Summary
  7.9.2 AbGenomics Business Overview
  7.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.9.4 AbGenomics Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.9.5 AbGenomics Key News
7.10 ADC Therapeutics
  7.10.1 ADC Therapeutics Corporate Summary
  7.10.2 ADC Therapeutics Business Overview
  7.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.10.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.10.5 ADC Therapeutics Key News
7.11 Astellas Pharma
  7.11.1 Astellas Pharma Corporate Summary
  7.11.2 Astellas Pharma Business Overview
  7.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.11.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.11.5 Astellas Pharma Key News
7.12 Kairos Therapeutics
  7.12.1 Kairos Therapeutics Corporate Summary
  7.12.2 Kairos Therapeutics Business Overview
  7.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Major Product Offerings
  7.12.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue in Global Market (2017-2022)
  7.12.5 Kairos Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Antibody Drug Conjugates (ADCs) Market Opportunities & Trends in Global Market
Table 2. Antibody Drug Conjugates (ADCs) Market Drivers in Global Market
Table 3. Antibody Drug Conjugates (ADCs) Market Restraints in Global Market
Table 4. Key Players of Antibody Drug Conjugates (ADCs) in Global Market
Table 5. Top Antibody Drug Conjugates (ADCs) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Antibody Drug Conjugates (ADCs) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Antibody Drug Conjugates (ADCs) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Antibody Drug Conjugates (ADCs) Product Type
Table 9. List of Global Tier 1 Antibody Drug Conjugates (ADCs) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antibody Drug Conjugates (ADCs) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Antibody Drug Conjugates (ADCs) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Antibody Drug Conjugates (ADCs) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Antibody Drug Conjugates (ADCs) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Antibody Drug Conjugates (ADCs) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Antibody Drug Conjugates (ADCs) Product Offerings
Table 32. Roche Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Antibody Drug Conjugates (ADCs) Product Offerings
Table 35. Pfizer Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Antibody Drug Conjugates (ADCs) Product Offerings
Table 38. Novartis Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 39. Genmab Corporate Summary
Table 40. Genmab Antibody Drug Conjugates (ADCs) Product Offerings
Table 41. Genmab Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 42. Bayer Corporate Summary
Table 43. Bayer Antibody Drug Conjugates (ADCs) Product Offerings
Table 44. Bayer Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 45. Seattle Genetics Corporate Summary
Table 46. Seattle Genetics Antibody Drug Conjugates (ADCs) Product Offerings
Table 47. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 48. Takeda Pharmaceuticals Corporate Summary
Table 49. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Offerings
Table 50. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 51. AbbVie Corporate Summary
Table 52. AbbVie Antibody Drug Conjugates (ADCs) Product Offerings
Table 53. AbbVie Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 54. AbGenomics Corporate Summary
Table 55. AbGenomics Antibody Drug Conjugates (ADCs) Product Offerings
Table 56. AbGenomics Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 57. ADC Therapeutics Corporate Summary
Table 58. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Offerings
Table 59. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 60. Astellas Pharma Corporate Summary
Table 61. Astellas Pharma Antibody Drug Conjugates (ADCs) Product Offerings
Table 62. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)
Table 63. Kairos Therapeutics Corporate Summary
Table 64. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Offerings
Table 65. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Antibody Drug Conjugates (ADCs) Segment by Type in 2021
Figure 2. Antibody Drug Conjugates (ADCs) Segment by Application in 2021
Figure 3. Global Antibody Drug Conjugates (ADCs) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Antibody Drug Conjugates (ADCs) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Antibody Drug Conjugates (ADCs) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Antibody Drug Conjugates (ADCs) Revenue in 2021
Figure 8. By Type - Global Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 12. US Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 16. Germany Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 17. France Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 24. China Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 28. India Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 30. Brazil Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue Market Share, 2017-2028
Figure 33. Turkey Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Antibody Drug Conjugates (ADCs) Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Genmab Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bayer Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. AbbVie Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. AbGenomics Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)